{"sent_idx": "78", "frame_idx": "7", "ev": "In contrast, in patients receiving bevacizumab single agent and in patients receiving lomustine single agent, CECs at baseline were similar to CECs after 4 weeks and 6 weeks of treatment.", "icos": [["1", "lomustine", "bevacizumab", "CECs"]], "sample": "x"}
{"sent_idx": "90", "frame_idx": "13", "ev": "We also found an association between higher absolute CEC numbers and improved overall survival during treatment with lomustine single agent, but not in bevacizumab-treated patients.", "icos": [["1", "lomustine", "bevacizumab", "absolute CEC numbers and improved overall survival"]], "sample": "x"}
{"sent_idx": "9", "frame_idx": "0", "ev": "In patients treated with lomustine single agent, higher absolute CEC numbers after 4 weeks (log10CEC hazard ratio (HR) 0.41, 95% CI 0.18\u20130.91) and 6 weeks (log10CEC HR 0.16, 95% CI 0.05\u20130.56) of treatment were associated with improved overall survival (OS).", "icos": [["0.9990068", "lomustine", "Lomustine", "overall survival ( OS )."], ["0.9990068", "lomustine", "lomustine", "overall survival ( OS )."], ["0.9893995", "lomustine", "cytotoxic chemotherapy", "overall survival ( OS )."], ["0.98138237", "lomustine", "lomustine cytotoxic chemotherapy", "overall survival ( OS )."], ["0.9099124", "lomustine", "bevacizumab plus lomustine , bevacizumab", "overall survival ( OS )."]], "sample": "c"}
{"sent_idx": "9", "frame_idx": "1", "ev": "In patients treated with lomustine single agent, higher absolute CEC numbers after 4 weeks (log10CEC hazard ratio (HR) 0.41, 95% CI 0.18\u20130.91) and 6 weeks (log10CEC HR 0.16, 95% CI 0.05\u20130.56) of treatment were associated with improved overall survival (OS).", "icos": [["0.99953306", "lomustine", "Lomustine", "absolute CEC numbers"], ["0.99953306", "lomustine", "lomustine", "absolute CEC numbers"], ["0.9988049", "lomustine", "lomustine and bevacizumab", "absolute CEC numbers"], ["0.9978898", "lomustine", "bevacizumab plus lomustine , bevacizumab", "absolute CEC numbers"], ["0.9975394", "lomustine", "bevacizumab plus lomustine", "absolute CEC numbers"]], "sample": "c"}
{"sent_idx": "10", "frame_idx": "2", "ev": "Absolute CEC numbers in patients receiving bevacizumab plus lomustine or bevacizumab single agent were not associated with OS.", "icos": [["0.99956363", "bevacizumab plus lomustine or bevacizumab", "Bevacizumab", "Absolute CEC numbers"], ["0.99956363", "bevacizumab plus lomustine or bevacizumab", "bevacizumab", "Absolute CEC numbers"], ["0.9995414", "bevacizumab plus lomustine or bevacizumab", "bevacizumab in combination with lomustine , bevacizumab single agent or lomustine", "Absolute CEC numbers"], ["0.99950707", "bevacizumab plus lomustine or bevacizumab", "bevacizumab plus lomustine", "Absolute CEC numbers"], ["0.9994124", "bevacizumab plus lomustine or bevacizumab", "bevacizumab plus lomustine , bevacizumab", "Absolute CEC numbers"]], "sample": "c"}
{"sent_idx": "19", "frame_idx": "3", "ev": "In patients treated with lomustine single agent, higher absolute CEC numbers after 4 weeks (log10CEC hazard ratio (HR) 0.41, 95% CI 0.18\u20130.91) and 6 weeks (log10CEC HR 0.16, 95% CI 0.05\u20130.56) of treatment were associated with improved overall survival (OS).", "icos": [["0.9990068", "lomustine", "Lomustine", "overall survival ( OS )."], ["0.9990068", "lomustine", "lomustine", "overall survival ( OS )."], ["0.9893995", "lomustine", "cytotoxic chemotherapy", "overall survival ( OS )."], ["0.98138237", "lomustine", "lomustine cytotoxic chemotherapy", "overall survival ( OS )."], ["0.9099124", "lomustine", "bevacizumab plus lomustine , bevacizumab", "overall survival ( OS )."]], "sample": "c"}
{"sent_idx": "19", "frame_idx": "4", "ev": "In patients treated with lomustine single agent, higher absolute CEC numbers after 4 weeks (log10CEC hazard ratio (HR) 0.41, 95% CI 0.18\u20130.91) and 6 weeks (log10CEC HR 0.16, 95% CI 0.05\u20130.56) of treatment were associated with improved overall survival (OS).", "icos": [["0.99953306", "lomustine", "Lomustine", "absolute CEC numbers"], ["0.99953306", "lomustine", "lomustine", "absolute CEC numbers"], ["0.9988049", "lomustine", "lomustine and bevacizumab", "absolute CEC numbers"], ["0.9978898", "lomustine", "bevacizumab plus lomustine , bevacizumab", "absolute CEC numbers"], ["0.9975394", "lomustine", "bevacizumab plus lomustine", "absolute CEC numbers"]], "sample": "c"}
{"sent_idx": "20", "frame_idx": "5", "ev": "Absolute CEC numbers in patients receiving bevacizumab plus lomustine or bevacizumab single agent were not associated with OS.", "icos": [["0.99956363", "bevacizumab plus lomustine or bevacizumab", "Bevacizumab", "Absolute CEC numbers"], ["0.99956363", "bevacizumab plus lomustine or bevacizumab", "bevacizumab", "Absolute CEC numbers"], ["0.9995414", "bevacizumab plus lomustine or bevacizumab", "bevacizumab in combination with lomustine , bevacizumab single agent or lomustine", "Absolute CEC numbers"], ["0.99950707", "bevacizumab plus lomustine or bevacizumab", "bevacizumab plus lomustine", "Absolute CEC numbers"], ["0.9994124", "bevacizumab plus lomustine or bevacizumab", "bevacizumab plus lomustine , bevacizumab", "Absolute CEC numbers"]], "sample": "c"}
{"sent_idx": "77", "frame_idx": "6", "ev": "In patients receiving bevacizumab plus lomustine combination therapy, patients had higher CECs after 4 weeks (P<0.001) and 6 weeks (P<0.001) of treatment compared with the baseline value.", "icos": [["0.99921584", "bevacizumab plus lomustine combination", "Bevacizumab", "CECs"], ["0.99921584", "bevacizumab plus lomustine combination", "bevacizumab", "CECs"], ["0.99856406", "bevacizumab plus lomustine combination", "bevacizumab plus lomustine combination", "CECs"], ["0.99850947", "bevacizumab plus lomustine combination", "bevacizumab plus lomustine", "CECs"], ["0.9927648", "bevacizumab plus lomustine combination", "bevacizumab plus lomustine , bevacizumab", "CECs"]], "sample": "c"}
{"sent_idx": "82", "frame_idx": "10", "ev": "In patients receiving bevacizumab plus lomustine and bevacizumab single agent, no significant associations between absolute CEC counts and OS were observed.", "icos": [["0.99950635", "bevacizumab plus lomustine and bevacizumab", "bevacizumab plus lomustine", "absolute CEC counts and OS"], ["0.9994266", "bevacizumab plus lomustine and bevacizumab", "Lomustine", "absolute CEC counts and OS"], ["0.9994266", "bevacizumab plus lomustine and bevacizumab", "lomustine", "absolute CEC counts and OS"], ["0.999374", "bevacizumab plus lomustine and bevacizumab", "Bevacizumab", "absolute CEC counts and OS"], ["0.999374", "bevacizumab plus lomustine and bevacizumab", "bevacizumab", "absolute CEC counts and OS"]], "sample": "c"}
{"sent_idx": "83", "frame_idx": "11", "ev": "However, in patients receiving lomustine single agent, an association between OS and higher absolute CEC counts at 4 weeks (log10CEC 4 weeks HR 0.41, 95% CI 0.18\u20130.91) and 6 weeks (log10CEC 6 weeks HR 0.16, 95% CI 0.05\u20130.56) was observed.", "icos": [["0.9994497", "lomustine", "Lomustine", "OS"], ["0.9994497", "lomustine", "lomustine", "OS"], ["0.99916303", "lomustine", "bevacizumab plus lomustine , bevacizumab", "OS"], ["0.99906856", "lomustine", "bevacizumab in combination with lomustine , bevacizumab single agent or lomustine", "OS"], ["0.998953", "lomustine", "lomustine cytotoxic chemotherapy", "OS"]], "sample": "c"}
{"sent_idx": "83", "frame_idx": "12", "ev": "However, in patients receiving lomustine single agent, an association between OS and higher absolute CEC counts at 4 weeks (log10CEC 4 weeks HR 0.41, 95% CI 0.18\u20130.91) and 6 weeks (log10CEC 6 weeks HR 0.16, 95% CI 0.05\u20130.56) was observed.", "icos": [["0.99944955", "lomustine", "Lomustine", "higher absolute CEC counts"], ["0.99944955", "lomustine", "lomustine", "higher absolute CEC counts"], ["0.99248075", "lomustine", "lomustine cytotoxic chemotherapy", "higher absolute CEC counts"], ["0.9883138", "lomustine", "bevacizumab plus lomustine , bevacizumab", "higher absolute CEC counts"], ["0.9820561", "lomustine", "bevacizumab plus lomustine", "higher absolute CEC counts"]], "sample": "c"}
